Enanta sues Pfizer, demanding compensation for Paxlovid-related patent infringement
Pfizer is seeing an uptick in litigation related to its mega-blockbuster Covid-19 vaccine and therapeutic, with the latest suit coming from Massachusetts-based Enanta Pharmaceuticals.
Enanta on Wednesday filed suit against Pfizer in district court in Massachusetts, seeking damages for infringement on a patent it originally filed back in July 2020.
Specifically, Enanta is claiming that Pfizer’s nirmatrelvir, the newly-developed half of Paxlovid, violates Enanta’s patent on multiple fronts for its protease inhibitor Covid-19 drug candidate. While Enanta said it does not want to halt the sale, distribution or production of Paxlovid, it also said it wants to be reimbursed with what it calls “fair compensation.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,900+ biopharma pros reading Endpoints daily — and it's free.